Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 3/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 10/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283811 | 0.92 | GRK5 (0.47) | GRK5GRK2METFGFR1FGFR3 | |
| SCHEMBL10283424 | 0.91 | MET (0.37) | GRK5GRK2METFGFR1FGFR3 | |
| SCHEMBL178094 | 0.89 | MET (0.44) | METFGFR1FGFR3 | |
| SCHEMBL14916826 | 0.88 | MET (0.39) | GRK5METFGFR1FGFR3FGFR2 | |
| SCHEMBL10283425 | 0.85 | MET (0.42) | METFGFR1FGFR3FGFR2 | |
| SCHEMBL360598 | 0.82 | PDE10A (0.38) | METFGFR1FGFR3 | |
| SCHEMBL359817 | 0.82 | MET (0.40) | METFGFR1FGFR3FGFR2 | |
| SCHEMBL255618 | 0.82 | PDE10A (0.38) | METFGFR1FGFR3FGFR2 | |
| SCHEMBL359940 | 0.82 | MET (0.41) | MET | |
| SCHEMBL360828 | 0.81 | MET (0.39) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | GRK5 92/4885GRK2 91/4885MET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.